The week in health tech, explained in plain English.Get the free newsletter →
October 11, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

Medicaid Cuts Push Family Caregivers Toward Financial Ruin

Family caregivers who are paid through Medicaid to care for disabled relatives are bracing for steep pay cuts as states move to absorb reductions in federal funding, STAT News reports. These caregivers, often parents or spouses, left traditional jobs to provide full-time home-based support and now depend on state-set wages that several states are preparing to slash.

The practical effect is severe. Programs that pay family members grew during the pandemic and became a lifeline for people with disabilities who need daily assistance but want to remain at home. Cutting those wages threatens household finances directly and could force families to give up caregiving altogether. When home-based care collapses, disabled people often end up in nursing homes or institutions, which typically cost states and Medicaid more, not less.

The squeeze reflects a broader tension: states facing tighter Medicaid budgets are targeting home- and community-based services, which are optional under federal rules and therefore among the first line items on the chopping block.

Sources

More in Government

Government

NIH Plans National Push on Personalized Cancer Vaccines

The NIH plans a December public-private partnership to accelerate development of personalized cancer vaccines, per a New York Times report.

Why it matters: A federally coordinated effort could accelerate a promising but fragmented field of custom cancer immunotherapies toward wider clinical use.

Government

White House Plans $100M STEM PhD Push as NIH Sheds Scientists

The Trump administration plans to put over $100 million into STEM PhD fellowships, announced at an Oct. 8 White House summit, even as the NIH loses scientists.

Why it matters: The PhD pipeline fuels biomedical research across hospitals and biotech, but new fellowship funding may not offset talent losses at the NIH.

Government

Stem Cell Advocates Eye FDA Opening Under RFK Jr.

Stem cell advocates hope the FDA will grant their unproven therapies legitimacy under RFK Jr., mirroring how peptides gained acceptance through the MAHA movement.

Why it matters: If regulatory politics rather than clinical evidence starts shaping FDA acceptance, it could reshape patient access and safety standards across emerging therapies.